DOSSIER · 13F-HR · Q2 2026

Elmind Capital, LP

$398M in tracked AUM across 35 positions as of Q2 2026.

EC
CIK 0002052213 · last filed Jun 30, 2026
Total AUM
$398M
as of Q2 2026
Holdings
35
positions
Whale Score
62
62
tracked
Activity
no data
changes this Q
AI Analysis · Q2 2026

Elmind Capital, LP filed its latest 13F-HR for Q2 2026. See the latest holdings and position changes below.

Quarter at a glance — Q2 2026

Position-change comparison pending.

No quarter-over-quarter changes available.

Top 10 holdings

By portfolio weight as of Q2 2026.

#HoldingValueSharesWeight
01
COGT
COGENT BIOSCIENCES INC
$45M1.2M11.4%
02
SNDX
SYNDAX PHARMACEUTICALS INC
$41M1.9M10.2%
03
CLDX
CELLDEX THERAPEUTICS INC NEW
$37M990K9.3%
04
RLAY
RELAY THERAPEUTICS INC
$27M1.5M6.9%
05
PCVX
VAXCYTE INC
$26M452K6.6%
06
VERA
VERA THERAPEUTICS INC
$19M437K4.7%
07
N69605108
PHARVARIS N V
$18M526K4.6%
08
VRDN
VIRIDIAN THERAPEUTICS INC
$18M985K4.5%
09
CTMX
CYTOMX THERAPEUTICS INC.
$17M4.5M4.3%
10
TVTX
TRAVERE THERAPEUTICS INC
$17M293K4.2%

Filing history

2026Q2Jun 30
$398M 17.5%
35 positionsView →
2025Q4Dec 31
$339M
34 positionsView →